Jpmorgan Chase & CO Brainstorm Cell Therapeutics Inc. Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
A detailed history of Jpmorgan Chase & CO transactions in Brainstorm Cell Therapeutics Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 255 shares of BCLI stock, worth $56. This represents 0.0% of its overall portfolio holdings.
Number of Shares
255
Previous 106
140.57%
Holding current value
$56
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding BCLI
# of Institutions
54Shares Held
12.3MCall Options Held
169KPut Options Held
30.6K-
Armistice Capital, LLC New York, NY7.92MShares$1.74 Million0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.51MShares$332,3400.0% of portfolio
-
Geode Capital Management, LLC Boston, MA484KShares$106,5420.0% of portfolio
-
Black Rock Inc. New York, NY386KShares$85,0110.0% of portfolio
-
Liberty Wealth Management LLC Oakland, CA340KShares$74,8330.02% of portfolio
About BRAINSTORM CELL THERAPEUTICS INC.
- Ticker BCLI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,486,200
- Market Cap $8.03M
- Description
- Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem ...